Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Positive top line results from Shire's LDX phase III study on ADHD

Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.

22 Oct 2011

FDA clears Cook Medical's Evolution Duodenal Controlled-Release Stent

Cook Medical announced today that its Evolution Duodenal Controlled-Release Stent was recently granted 510(k) clearance by the Food & Drug Administration.

18 Oct 2011

Scientists discover a way to accurately map typhoid outbreaks in the city

In the mid-nineteenth century, John Snow mapped cases of cholera in Soho, London, and traced the source of the outbreak to a contaminated water pump. Now, in a twenty-first century equivalent, scientists funded by the Wellcome Trust working in Kathmandu, Nepal, have combined the latest in gene sequencing technology and global positioning system (GPS) case localisation to map the spread of typhoid and trace its source.

18 Oct 2011

Patients with episodic gallbladder pain may benefit from cholecystectomy

According to a new study in Clinical Gastroenterology and Hepatology, better understanding of a patient's abdominal pain could help physicians know which patients will benefit most from surgical removal of the gallbladder.

14 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

MD Anderson's pediatric surgeon receives Geneva and James Briscoe Physician Assistant Award

Holly Green, a pediatric surgery physician assistant in the Department of Surgical Oncology, division of pediatrics at The University of Texas MD Anderson Children's Cancer Hospital, is the recipient of the 2011 Geneva and James Briscoe Physician Assistant Award for Excellence.

7 Oct 2011

Federal officials extend Ariz. Medicaid program while reviewing new plan; Wis. announces eligibility changes to cut budget shortfall

In other state Medicaid news, doctors in Washington state are suing to stop a new rule that limits enrollees' visits to the emergency department and Gov. Cuomo's administration dismisses a proposal for N.Y. to pay for transgender surgery.

4 Oct 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Almirall seeks European approval for linaclotide to treat irritable bowel syndrome with constipation

Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.

29 Sep 2011

Almirall submits linaclotide MAA to EMA for treatment of IBS-C

Ironwood Pharmaceuticals, Inc. today announced that its European partner Almirall, S.A. submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for linaclotide, a guanylate cyclase type-C (GC-C) agonist, for the treatment of irritable bowel syndrome with constipation.

29 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.

26 Sep 2011

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea.

26 Sep 2011

Janssen Biotech receives FDA approval for Remicade to treat UC in children

The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy.

26 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

Experts urge women to recognize warning signs of ovarian cancer, receive appropriate screenings

Ovarian cancer is a rare but often deadly disease that can strike at any time in a woman's life. It affects one in 70 women and in the past was referred to as a silent killer, but researchers have found there are symptoms associated with ovarian cancer that can assist in early detection. Experts at Northwestern Memorial say the best defense is to make use of preventive methods, understand the risks and recognize potential warning signs of ovarian cancer.

16 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Abdominal Pain News and Research

Further Reading

Positive top line results from Shire's LDX phase III study on ADHD

FDA clears Cook Medical's Evolution Duodenal Controlled-Release Stent

Scientists discover a way to accurately map typhoid outbreaks in the city

Patients with episodic gallbladder pain may benefit from cholecystectomy

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

MD Anderson's pediatric surgeon receives Geneva and James Briscoe Physician Assistant Award

Federal officials extend Ariz. Medicaid program while reviewing new plan; Wis. announces eligibility changes to cut budget shortfall

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Almirall seeks European approval for linaclotide to treat irritable bowel syndrome with constipation

Almirall submits linaclotide MAA to EMA for treatment of IBS-C

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Janssen Biotech receives FDA approval for Remicade to treat UC in children

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Experts urge women to recognize warning signs of ovarian cancer, receive appropriate screenings

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News